AstraZeneca Halts Early KRASG12D Cancer Trial, Shifting Focus in Competitive Oncology Race
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca’s latest update covers ALAFOSS-01, a first-in-human Phase I/IIa trial of AZD0022 in adults with advanced cancers carrying a KRASG12D mutation. The study aimed to test safety, dosing, and early signs of benefit in tough tumors such as NSCLC, pancreatic, and colorectal cancer, areas with high unmet need and strong commercial interest.
The trial tested AZD0022, an oral drug designed to block KRASG12D, a key cancer driver mutation. It was assessed alone and in combination with the antibody drug cetuximab, which targets EGFR and is already used in some colorectal and head and neck cancers.
The study used an interventional design with non-random allocation, meaning all patients received active treatment rather than placebo. It was open-label and sequential, so both doctors and patients knew which treatment was given, and dose levels were adjusted step-by-step to find an optimal and safe range.
The trial began after initial submission in August 2024, with early phases focused on dose escalation and safety. The listing now shows the study status as terminated, with the latest update posted March 5, 2026, signaling that AZD0022 will not move forward under this protocol.
For investors, termination of this KRASG12D program is a setback for AstraZeneca’s precision oncology pipeline and may weigh modestly on sentiment around its early-stage assets. However, the broader KRAS race remains active, with players like Amgen and Mirati/Bristol Myers targeting other KRAS mutations, so attention is likely to shift to AZN’s remaining oncology portfolio and alternative pipeline bets.
The ALAFOSS-01 study of AZD0022 has been terminated and the listing was recently updated, with further details available on the ClinicalTrials.gov portal.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
